Hemolytic uremic syndrome caused by Shiga toxin-producing Escherichia coli in children: incidence, risk factors, and clinical outcome.


Journal

Pediatric nephrology (Berlin, Germany)
ISSN: 1432-198X
Titre abrégé: Pediatr Nephrol
Pays: Germany
ID NLM: 8708728

Informations de publication

Date de publication:
09 2020
Historique:
received: 11 10 2019
accepted: 30 03 2020
revised: 22 03 2020
pubmed: 24 4 2020
medline: 16 6 2021
entrez: 24 4 2020
Statut: ppublish

Résumé

Hemolytic uremic syndrome (HUS) is a multisystemic disease. In a nationwide study, we characterized the incidence, clinical course, and prognosis of HUS caused by Shiga toxin (Stx)-producing Escherichia coli (STEC) strains with emphasis on risk factors, disease severity, and long-term outcome. The data on pediatric HUS patients from 2000 to 2016 were collected from the medical records. STEC isolates from fecal cultures of HUS and non-HUS patients were collected from the same time period and characterized by whole genome sequencing analysis. Fifty-eight out of 262 culture-positive cases developed verified (n = 58, 22%) STEC-HUS. Another 29 cases had probable STEC-HUS, the annual incidence of STEC-HUS being 0.5 per 100,000 children. Eleven different serogroups were detected, O157 being the most common (n = 37, 66%). Age under 3 years (OR 2.4), stx2 (OR 9.7), and stx2a (OR 16.6) were found to be risk factors for HUS. Fifty-five patients (63%) needed dialysis. Twenty-nine patients (33%) developed major neurological symptoms. Complete renal recovery was observed in 57 patients after a median 4.0 years of follow-up. Age under 3 years, leukocyte count over 20 × 10 Age under 3 years, stx2, and stx2a were risk factors for HUS in STEC-positive children. However, serogroup or stx types did not predict the renal outcome or major CNS symptoms.

Sections du résumé

BACKGROUND
Hemolytic uremic syndrome (HUS) is a multisystemic disease. In a nationwide study, we characterized the incidence, clinical course, and prognosis of HUS caused by Shiga toxin (Stx)-producing Escherichia coli (STEC) strains with emphasis on risk factors, disease severity, and long-term outcome.
METHODS
The data on pediatric HUS patients from 2000 to 2016 were collected from the medical records. STEC isolates from fecal cultures of HUS and non-HUS patients were collected from the same time period and characterized by whole genome sequencing analysis.
RESULTS
Fifty-eight out of 262 culture-positive cases developed verified (n = 58, 22%) STEC-HUS. Another 29 cases had probable STEC-HUS, the annual incidence of STEC-HUS being 0.5 per 100,000 children. Eleven different serogroups were detected, O157 being the most common (n = 37, 66%). Age under 3 years (OR 2.4), stx2 (OR 9.7), and stx2a (OR 16.6) were found to be risk factors for HUS. Fifty-five patients (63%) needed dialysis. Twenty-nine patients (33%) developed major neurological symptoms. Complete renal recovery was observed in 57 patients after a median 4.0 years of follow-up. Age under 3 years, leukocyte count over 20 × 10
CONCLUSIONS
Age under 3 years, stx2, and stx2a were risk factors for HUS in STEC-positive children. However, serogroup or stx types did not predict the renal outcome or major CNS symptoms.

Identifiants

pubmed: 32323005
doi: 10.1007/s00467-020-04560-0
pii: 10.1007/s00467-020-04560-0
pmc: PMC7385025
doi:

Substances chimiques

Creatinine AYI8EX34EU

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1749-1759

Références

Infect Immun. 2011 Mar;79(3):1329-37
pubmed: 21199911
Pediatr Nephrol. 2013 Nov;28(11):2097-105
pubmed: 23288350
J Infect Dis. 2002 Jan 1;185(1):74-84
pubmed: 11756984
JAMA. 2003 Sep 10;290(10):1360-70
pubmed: 12966129
BMC Infect Dis. 2015 Aug 11;15:324
pubmed: 26259588
J Pediatr. 2015 Apr;166(4):1022-9
pubmed: 25661408
J Clin Microbiol. 2007 Jun;45(6):2020-4
pubmed: 17446326
Pediatr Nephrol. 2018 Dec;33(12):2371-2381
pubmed: 30159625
BMJ Open. 2016 Jan 29;6(1):e009933
pubmed: 26826153
BMC Infect Dis. 2014 May 16;14:265
pubmed: 24884396
Epidemiol Infect. 2015 Dec;143(16):3475-87
pubmed: 25920912
Nat Rev Nephrol. 2012 Nov;8(11):658-69
pubmed: 22986362
Clin Infect Dis. 2013 May;56(10):1373-81
pubmed: 23378282
Arch Dis Child. 2001 Aug;85(2):125-31
pubmed: 11466187
J Pediatr. 1991 Feb;118(2):195-200
pubmed: 1993944
Med Mal Infect. 2018 May;48(3):167-174
pubmed: 29054297
Kidney Int. 2018 Aug;94(2):408-418
pubmed: 29907460
Emerg Infect Dis. 2016 Sep;22(9):1604-12
pubmed: 27533474
Sci Rep. 2019 Apr 4;9(1):5619
pubmed: 30948755
Pediatr Nephrol. 2008 Aug;23(8):1303-8
pubmed: 18465151
Pediatrics. 2017 Sep;140(3):
pubmed: 28827377
J Infect Dis. 1998 Apr;177(4):962-6
pubmed: 9534969
N Engl J Med. 2000 Jun 29;342(26):1930-6
pubmed: 10874060
Clin Infect Dis. 2006 Dec 15;43(12):1587-95
pubmed: 17109294
Euro Surveill. 2018 Aug;23(35):
pubmed: 30180926
Pediatr Nephrol. 2010 Sep;25(9):1693-8
pubmed: 20422224
Lancet. 2005 Mar 19-25;365(9464):1073-86
pubmed: 15781103
Arch Public Health. 2018 Aug 6;76:41
pubmed: 30128150
J Pediatric Infect Dis Soc. 2016 Jun;5(2):147-51
pubmed: 27199470
JAMA. 2002 Aug 28;288(8):996-1001
pubmed: 12190370
Epidemiol Infect. 2018 Sep 5;:1-5
pubmed: 30182864
Emerg Infect Dis. 2005 Apr;11(4):590-6
pubmed: 15829199
J Comput Biol. 2012 May;19(5):455-77
pubmed: 22506599
Eur J Pediatr. 2010 May;169(5):591-8
pubmed: 19830454
Eur J Pediatr. 2010 Jan;169(1):7-13
pubmed: 19707787
Front Cell Infect Microbiol. 2018 May 01;8:125
pubmed: 29765909
N Engl J Med. 2011 Nov 10;365(19):1763-70
pubmed: 22029753
N Engl J Med. 2011 Nov 10;365(19):1771-80
pubmed: 21696328
Clin Infect Dis. 2012 May;54(10):1413-21
pubmed: 22412065
Kidney Int. 2012 Aug;82(4):445-53
pubmed: 22622496
J Infect Dis. 2002 Aug 15;186(4):493-500
pubmed: 12195376
Am J Epidemiol. 2002 May 15;155(10):941-8
pubmed: 11994234
Foodborne Pathog Dis. 2013 May;10(5):453-60
pubmed: 23560425
Bioinformatics. 2014 Jul 15;30(14):2068-9
pubmed: 24642063
BMC Bioinformatics. 2009 Dec 15;10:421
pubmed: 20003500

Auteurs

Elisa Ylinen (E)

Department of Pediatric Nephrology and Transplantation, New Children's Hospital, University of Helsinki and Helsinki University Hospital|, P.O. Box 347, 00029 HUS, Helsinki, Finland. elisa.ylinen@hus.fi.

Saara Salmenlinna (S)

Department of Health Security, Finnish Institute for Health and Welfare (THL), Helsinki, Finland.

Jani Halkilahti (J)

Department of Health Security, Finnish Institute for Health and Welfare (THL), Helsinki, Finland.

Timo Jahnukainen (T)

Department of Pediatric Nephrology and Transplantation, New Children's Hospital, University of Helsinki and Helsinki University Hospital|, P.O. Box 347, 00029 HUS, Helsinki, Finland.

Linda Korhonen (L)

Department of Children and Adolescents, Oulu University Hospital, Oulu, Finland.
PEDEGO Research Unit, Research Unit for Pediatrics, Dermatology, Clinical Genetics, Obstetrics and Gynecology, Medical Research Center Oulu (MRC Oulu), Oulu, Finland.

Tiia Virkkala (T)

Department of Pediatric Nephrology and Transplantation, New Children's Hospital, University of Helsinki and Helsinki University Hospital|, P.O. Box 347, 00029 HUS, Helsinki, Finland.

Ruska Rimhanen-Finne (R)

Department of Health Security, Finnish Institute for Health and Welfare (THL), Helsinki, Finland.

Matti Nuutinen (M)

Department of Children and Adolescents, Oulu University Hospital, Oulu, Finland.
PEDEGO Research Unit, Research Unit for Pediatrics, Dermatology, Clinical Genetics, Obstetrics and Gynecology, Medical Research Center Oulu (MRC Oulu), Oulu, Finland.

Janne Kataja (J)

Department of Pediatrics and Adolescent Medicine, Turku University Hospital, Turku, Finland.

Pekka Arikoski (P)

Department of Pediatrics, Kuopio University Hospital and University of Eastern Finland, Kuopio, Finland.

Laura Linkosalo (L)

Department of Pediatrics, Tampere University Hospital, Tampere, Finland.

Xiangning Bai (X)

Division of Clinical Microbiology, Department of Laboratory Medicine, Karolinska University Laboratory, Stockholm, Sweden.

Andreas Matussek (A)

Division of Clinical Microbiology, Department of Laboratory Medicine, Karolinska University Laboratory, Stockholm, Sweden.
Division of Laboratory Medicine, Oslo University Hospital, Oslo, Norway.

Hannu Jalanko (H)

Department of Pediatric Nephrology and Transplantation, New Children's Hospital, University of Helsinki and Helsinki University Hospital|, P.O. Box 347, 00029 HUS, Helsinki, Finland.

Harri Saxén (H)

Department of Pediatric Nephrology and Transplantation, New Children's Hospital, University of Helsinki and Helsinki University Hospital|, P.O. Box 347, 00029 HUS, Helsinki, Finland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH